drugset / Trial / NCT02417207
Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to observe a new scheme can achieve is the same as the traditional scheme of the effect of preventing hepatitis B recurrence.
Timeline
- Start
- 2015-04
- Primary completion
- 2018-04
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Entecavir | Small molecule | — | — |
| Comparator | hepatitis B immune globulin | Protein / enzyme biologic | 400 iu | Intramuscular |
| Comparator | hepatitis B immune globulin | Protein / enzyme biologic | 2000 iu | Intramuscular |
| Comparator | hepatitis B immune globulin | Protein / enzyme biologic | 2500 iu | Intramuscular |
| Comparator | hepatitis B immune globulin | Protein / enzyme biologic | 5000 iu | Intramuscular |